Avadel Pharmaceuticals plc (AVDL) Stock

About Avadel Pharmaceuticals plc

Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.

Avadel Pharmaceuticals plc is headquartered in IE.

Avadel Pharmaceuticals plc (AVDL) stock trades at $21.64 with a market capitalization of $2.12B. The stock is valued at a price-to-earnings (P/E) ratio of 431.08, price-to-book of 21.39, price-to-sales of 10.72. Over the past 52 weeks the stock has ranged between $6.38 and $23.57, and currently trades 8.2% below its 52-week high.

On profitability, Avadel Pharmaceuticals plc generates a return on equity (ROE) of 5.44%, return on capital employed of 5.71%, an operating margin of 3.95%, a net profit margin of 2.41%.

Official website: www.avadel.com

Avadel Pharmaceuticals plc by the numbers, 2015–2024

Between 2015 and 2024 Avadel Pharmaceuticals plc reported revenue of $173.0M rising to $169.0M, a change of -2.3% across 10 years. Compounded, revenue has grown 23.4% a year over five years, —% over three, 503.6% over the last twelve months. Net profit fell to $-49.0M.

Operating margin went from 41.3% in 2015 to -25.1% in 2024, a fall of 66.3 percentage points. The most recent net margin is 2.41%. On a trailing twelve-month basis to Sep '25, revenue is $248.0M and net profit $0.

Borrowings rose from $1.0M to $2.0M, cash on hand is $91.6M, cash from operations was $-47.0M in the latest year, positive in 3 of the last 10.

Return on equity has averaged 62.0% over five years, and was -66.2% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Avadel Pharmaceuticals plc (AVDL) — frequently asked questions